• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Woiwode Thomas

    7/6/21 6:01:21 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care
    Get the next $MLND alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Woiwode Thomas

    (Last) (First) (Middle)
    7000 SHORELINE COURT
    SUITE 275

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tempest Therapeutics, Inc. [ TPST ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/01/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $11.07 07/01/2021 A 6,635 (1) 06/30/2031 Common Stock 6,635 (1) 6,635 D
    Explanation of Responses:
    1. One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service.
    /s/ Pierre Lorenzo, attorney-in-fact for Thomas Woiwode 07/06/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MLND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest and Millendo Announce Stockholder Approval of Merger

    SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. ("Tempest"), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (NASDAQ:MLND) ("Millendo"), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June 22, 2021. The stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. The closing of the merger is anticipated to take place on or around Friday, June 25, 2021. Following the closin

    6/22/21 4:00:00 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    Tempest and Millendo Announce Proposed Merger Agreement

    SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Tempest Therapeutics, Inc. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today that they have entered into a definitive agreement under which Millendo will merge with Tempest in an all-stock transaction. The combined company will focus on advancing Tempest’s oncology pipeline of small molecule therapeutics that have the potential to address a wide range of tumors. Upon shareholder approval, the combined company is expected to

    3/29/21 7:00:00 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    $MLND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: Versant Venture Capital VI, L.P. claimed ownership of 2,176,411 units of Common Stock

    3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/6/21 6:26:38 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Xu Stella

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/6/21 6:05:53 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Woiwode Thomas

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    7/6/21 6:01:21 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    $MLND
    SEC Filings

    View All

    Millendo Therapeutics, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    7/7/21 5:18:29 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K/A filed by Millendo Therapeutics, Inc. (Amendment)

    8-K/A - Millendo Therapeutics, Inc. (0001544227) (Filer)

    7/1/21 4:44:35 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    Millendo Therapeutics, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Millendo Therapeutics, Inc. (0001544227) (Filer)

    6/28/21 8:51:29 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    $MLND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Millendo Therapeutics, Inc.

    SC 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)

    7/8/21 4:25:45 PM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Millendo Therapeutics, Inc.

    SC 13G - Tempest Therapeutics, Inc. (0001544227) (Subject)

    7/6/21 10:59:33 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Millendo Therapeutics, Inc. (Amendment)

    SC 13D/A - Millendo Therapeutics, Inc. (0001544227) (Subject)

    4/13/21 10:06:27 AM ET
    $MLND
    Major Pharmaceuticals
    Health Care